CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 198 enrolled
Drug / intervention
donepezil hydrochloride +1 moredrug
Likely dose
donepezil hydrochloride 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00369785
NCT00369785Phase 3Completed

Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain

Wake Forest University Health Sciences·interventional·Posted Aug 29, 2006·Updated Oct 20, 2021

In Brief

A Phase 3 clinical trial evaluating donepezil hydrochloride and Placebo for Brain Tumors and Metastatic Disease. Completed, enrolled 198 participants across 16 sites.

Detailed Summary

RATIONALE: Donepezil may help lessen confusion and fatigue and improve mood and quality of life in patients who have undergone radiation therapy for brain tumors. It is not yet known whether donepezil is more effective than a placebo in lessening side effects of radiation therapy in patients with brain tumors. PURPOSE: This randomized phase III trial is studying donepezil to see how well it works in lessening side effects of radiation therapy compared with a placebo in patients who have undergone radiation therapy for brain tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 29, 2006
Enrollment StartFeb 1, 2008
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 19.8 years ago

Interventions

donepezil hydrochloridedrug

Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily

Placebodrug

Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day